A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer

详细信息    查看全文

• 作者：Nicholas M. Donin ; M.D.^a ; ^{NDonin@mednet.ucla.edu} ; Karim Chamie ; M.D. ; M.S.H.S.^a ; Andrew T. Lenis ; M.D. ; M.S.^a ; Allan J. Pantuck ; M.D. ; M.S.^a ; Madhu Reddy ; M.D.^b ; Dana Kivlin ; M.D.^b ; Johanna Holldack ; M.D.^c ; Rafaella Pozzi ; PharmD^c ; Gil Hakim ; B.Sc^g ; Lawrence I. Karsh ; M.D.^d ; Donald L. Lamm ; M.D.^e ; Laurence H. Belkoff ; D.O.^b ; Arie S. Belldegrun ; M.D.^a ; Stuart Holden ; M.D.^a ; Neal Shore ; M.D.^f
• 关键词：Imiquimod ; Urinary bladder neoplasms ; Carcinoma in situ ; Administrations ; intravesical drug ; Immunotherapy
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：35
• 期：2
• 页码：39.e1-39.e7
• 全文大小：210 K
• 卷排序：35

文摘

TMX-101 0.4% is a novel intravesical formulation of imiquimod, a toll-like receptor agonist. In this phase-2 study of patients with CIS, TMX-101 had an excellent safety profile. Activity was suggested by significant increases in urinary cytokines including IL-18. A total of 2 patients demonstrated a complete response 6 weeks following treatment.